Sarah Kehl, MD
Allergy & Immunology · Eugene, ORNPI 1992835367
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 131 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 27.2% of the total.
Across 131 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$783
- GSK$427
- Blueprint Medicines Corporation$242
- Octapharma USA, Inc.$162
- Sanofi$153
- CSL Behring$153
- plus $960 from 15 others
Across 12 payments — averaging $13,371 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hikma Pharmaceuticals USA$155K
- Cipla USA Inc.$5K
What the payments were for
- Consulting fees$602%
- Food & beverage$2,81898%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $783 |
| GSK | 34 | $427 |
| Blueprint Medicines Corporation | 5 | $242 |
| Octapharma USA, Inc. | 5 | $162 |
| Sanofi | 8 | $153 |
| CSL Behring | 10 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $140 |
| Alk-abello, Inc | 2 | $130 |
| Regeneron Healthcare Solutions, Inc. | 4 | $97 |
| Pfizer | 4 | $94 |
| Amgen(2 entities) | 4 | $85 |
| Genentech USA, Inc. | 6 | $68 |
| Novartis | 3 | $64 |
| ADMA Biomanufacturing LLC | 2 | $60 |
| Pharming Healthcare, Inc. | 3 | $52 |
| Teva Pharmaceuticals USA, Inc. | 2 | $46 |
| AbbVie | 2 | $35 |
| Boehringer Ingelheim | 2 | $31 |
| LEO Pharma Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $20 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,879 in reported general payments places this provider in the 60th percentile of 33 allergy & immunology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 16 | $58,344 |
| Dupixent SyringeDupilumab | 15 | $53,337 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $51,600 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $30,827 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $20,784 |
| Spiriva RespimatTiotropium Bromide | 26 | $19,702 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $17,162 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 62 | $15,686 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 89 | $12,894 |
| Arnuity ElliptaFluticasone Furoate | 31 | $9,374 |
| Qvar RedihalerBeclomethasone Dipropionate | 22 | $7,743 |
| DuleraMometasone/Formoterol | 19 | $6,284 |
| Epinephrine | 16 | $3,650 |
| Montelukast Sodium | 286 | $3,457 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 123 | $3,442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $427 | $81,759130 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $783 | $47,98980 claims |
| Boehringer IngelheimSpiriva Respimat | $31 | $19,70226 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $46 | $7,74322 claims |
| MerckDulera | $15 | $6,28419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 33 allergy & immunology providers in Oregon.
Other allergy & immunology in Eugene
- Kraig JacobsonEugene$7K
- Maxwell LiEugene$5K
- Jason FriesenEugene$2K
- Richard BuckEugene$501
- Adam WilliamsBend$138K
- Shyam JoshiPortland$116K
- Stephen FritzHappy Valley$42K
- Anthony MontanaroPortland$25K
- Karen AnsteyPortland$20K
- Michael OsbornePortland$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.